PHAXIAM Therapeutics S.A. (0QSS.L) LSE
Currency In EUR
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In EUR
Sector
Healthcare
Industry
Biotechnology
Employees
68
First IPO Date
September 19, 2014
| Name | Title | Pay | Year Born |
| Jérôme Bailly | Deputy Chief Executive Officer, Deputy GM, Chief Quality Officer & Qualified Person | 257,789 | 1979 |
| Thibaut du Fayet | Chief Executive Officer | 355,471 | 1968 |
| Eric Raymond | Consultant & Member of Scientific Board | 0 | N/A |
| Pascal Birman | Chief Medical Officer | 0 | N/A |
| Frédéric Mathat | Chief Financial Officer | 0 | N/A |
| Cindy Fevre | Chief Scientific Officer | 0 | N/A |
| Naomi Eichenbaum | Director Investor Relations | 0 | N/A |
| Bridget Bax | Consultant & Member of Scientific Board | 0 | N/A |
| Philip L. Lorenzi | Consultant & Member of Scientific Board | 0 | N/A |
| Arthur E. Frankel | Consultant & Member of Scientific Board | 0 | N/A |
Operating in France and the United States, PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for treating advanced pancreatic cancer (second-line), and in Phase 2 for both triple-negative breast cancer and acute lymphoblastic leukemia (second-line). Additionally, PHAXIAM is advancing a range of phage-based therapies designed to combat hazardous, drug-resistant bacteria. These particular pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of persistent hospital-acquired infections. Formerly known as ERYTECH Pharma S.A., the company officially adopted the name PHAXIAM Therapeutics S.A. in June 2023. Established in 2004, its headquarters are located in Lyon, France.